About us

Chairman and founding member of CSP who has raised over $1bn for various life sciences over his career.  Previously, he founded and grew Circassia Pharmaceuticals into an international respiratory business including setting up direct sales operations in China. He is a founding member and Chairman of Synchrony Pharma. He was a founding member of the management team that grew ZeneusPharma into a successful specialty pharmaceutical company and managed its acquisition by Cephalon Inc. (now part of Teva).

Strategic leader with extensive international experience, gained in a number of senior roles. Prior to joining CS Pharmaceuticals, he was SVP Commercial at Circassia Pharmaceuticals, responsible for the Ex US business and in particular the expansion of the business in China resulting in significant sales growth and reimbursement in a number of provinces for the lead product. Prior to joining Circassia he spent 10 years at Takeda Pharmaceuticals where he was Head of Commercial Operations, Asia Pacific.

SVP, Greater China for EVERSANA Services and has significant experience in healthcare in China.

Prior to joining EVERSANA, Roberto was Managing Director of Cardinal Health China (KDL) within Shanghai Pharmaceutical Group (SPG), the 2nd largest healthcare distributor in China and one of the largest state-owned enterprises in China and revenues > $25B USD and Fortune 500 company.

Roberto joined SPG through its acquisition of KDL where he was Chief Commercial Officer.

Professor Andrew Wilks is a serial entrepreneur with 20 years commercial experience, following a successful academic career at the Ludwig Institute for Cancer Research. Andrew has discovered and named many novel protein kinases, including the JAK family of kinases, and went on to found Cytopia in 1997. Since then, Andrew has founded or co-founded ten drug discovery companies. In particular, he is co-founder of SYNthesis med chem, a global contract chemistry group with laboratories in China and more than 250 scientists world-wide.

Chairman and founding partner of WG Partners, a life science financial advisory company that has raised over $8.2bn for life science companies over the last 10 years.

David has over 30 years’ experience in investment banking in the City of London. Previously he was CEO of Piper Jaffray Ltd, where he also served as Global Chairman of Healthcare and on the Group Leadership Team. David has held senior positions at number of financial institutions.

John Dawson CBE, joined Oxford Biomedica’s Board as a Non-Executive Director in August 2008, and was appointed Chief Executive Officer from October 2008 until January 2022. Prior to this he held senior management positions in the European operations of Cephalon Inc., including Chief Financial Officer and Head of Business Development Europe. While at Cephalon he led many deals building the European business to over 1,000 people and to a turnover of several hundred million US dollars.

Professor Bruce Robinson is an endocrinologist with over 40 years medical and research experience and has published over 300 peer-reviewed scientific articles. During his career, Bruce has been Dean of Medicine at the University of Sydney, Chair of the National Health and Medical Research Council (NHMRC) and Chair of the Medical Benefits Schedule Taskforce in Australia. Over the last 12 years, Bruce has been a non-executive director in a number of ASX-listed healthcare companies including Cochlear Limited, Mayne Pharma Limited and QBiotics Group.